Meiji Yasuda America Inc Purchases New Holdings in Insulet Corporation $PODD

Meiji Yasuda America Inc purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,816 shares of the medical instruments supplier’s stock, valued at approximately $3,643,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its stake in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after acquiring an additional 142,922 shares during the period. ING Groep NV increased its stake in Insulet by 88.5% during the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after acquiring an additional 8,123 shares during the period. Jain Global LLC increased its stake in Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after acquiring an additional 63,719 shares during the period. Fisher Asset Management LLC increased its stake in Insulet by 38.1% during the third quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock valued at $14,286,000 after acquiring an additional 12,754 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp increased its stake in Insulet by 26.5% during the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after acquiring an additional 9,206 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PODD. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Raymond James Financial set a $216.00 price objective on Insulet in a report on Monday. UBS Group set a $219.00 price objective on Insulet in a report on Thursday. JPMorgan Chase & Co. decreased their price objective on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday, May 7th. Finally, Truist Financial set a $219.00 price objective on Insulet in a report on Thursday. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $240.78.

Insulet Stock Down 1.0%

NASDAQ PODD opened at $149.19 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock’s 50 day moving average is $171.07 and its two-hundred day moving average is $233.25. The company has a market capitalization of $10.33 billion, a price-to-earnings ratio of 34.70, a PEG ratio of 1.19 and a beta of 1.13. Insulet Corporation has a 1-year low of $140.63 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is owned by insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.